Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

Kojiro Shimozuma, Yasuo Ohashi, Ayano Takeuchi, Toshihiko Aranishi, Satoshi Morita, Katsumasa Kuroi, Shozo Ohsumi, Haruhiko Makino, Hirohumi Mukai, Noriyuki Katsumata, Yoshihide Sunada, Toru Watanabe, Frederick H. Hausheer

研究成果: Article査読

108 被引用数 (Scopus)

抄録

Goals: The aim of the study was to determine the feasibility and validity of a newly developed patient-based instrument-the Patient Neurotoxicity Questionnaire (PNQ)-for grading chemotherapy-induced peripheral neuropathy (CIPN). Patients and methods: We prospectively collected data from 300 female patients who were treated with taxane chemotherapy for primary breast cancer as part of a national multicenter phase III randomized trial (N-SAS BC 02). We evaluated patient compliance with the PNQ and several validation parameters, including concordance between CIPN grades noted by physicians (National Cancer Institute Common Toxicity Criteria) and patients (PNQ), and the concurrent validity and responsiveness of the PNQ versus the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) utilizing data at pre-treatment and before three, five, and seven treatment cycles. Main results: The questionnaire completion rate was >90% at all assessments. Evaluation by physicians always resulted in lower neuropathy assessment scores compared with those reported directly by patients (weighted kappa coefficients, 0.02-0.06). Both PNQ sensory and motor scores were significantly correlated with the FACT/GOG-Ntx (r∈=∈0.66 and 0.51, respectively). In the repeated measures analysis of variance model, PNQ grades increased considerably as treatment continued, indicating progressively worsening CIPN over time. Conclusions: The PNQ has an applicable degree of feasibility and validity, useful for the diagnosis of CIPN as well as for clinical treatment decision-making, where the development of CIPN is a potential treatment-limiting consideration. Physicians underreport and underestimate the severity of CIPN symptoms compared with patients, thereby supporting the importance of assessing patient-reported outcomes using the PNQ.

本文言語English
ページ(範囲)1483-1491
ページ数9
ジャーナルSupportive Care in Cancer
17
12
DOI
出版ステータスPublished - 2009 12月
外部発表はい

ASJC Scopus subject areas

  • 腫瘍学

フィンガープリント

「Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル